Idioma:

The gold complex auranofin: new perspectives for cancer therapy

Abdalbari, Farah H. ; Telleria, Carlos M.

Discover. Oncology, 2021-10, Vol.12 (1), p.42-42, Article 42 [Revista revisada por pares]

New York: Springer US

Texto completo disponible

Citas Citado por

Acciones

Título:
The gold complex auranofin: new perspectives for cancer therapy
Autor: Abdalbari, Farah H. ; Telleria, Carlos M.
Materias: Antioxidants ; Apoptosis ; Auranofin ; Cancer ; Cancer Research ; Cancer therapies ; Cell death ; Cell growth ; Chemotherapy ; Cisplatin ; Cytotoxicity ; Disease ; Enzymes ; Gold ; Immunogenic cell death ; Inflammation ; Internal Medicine ; Kinases ; Ligands ; Mass spectrometry ; Medical prognosis ; Medicine ; Medicine & Public Health ; Molecular Medicine ; Nonsteroidal anti-inflammatory drugs ; Oncology ; Ovarian cancer ; Oxidation ; Oxidative stress ; Patients ; Perspective ; Phosphatase ; Proteins ; Radiotherapy ; Rheumatoid arthritis ; Scientific imaging ; Surgical Oncology ; Thioredoxin reductase ; Tuberculosis ; Tumorigenesis ; Tumors
Es parte de: Discover. Oncology, 2021-10, Vol.12 (1), p.42-42, Article 42
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descripción: Advanced stages of cancer are highly associated with short overall survival in patients due to the lack of long-term treatment options following the standard form of care. New options for cancer therapy are needed to improve the survival of cancer patients without disease recurrence. Auranofin is a clinically approved agent against rheumatoid arthritis that is currently enrolled in clinical trials for potential repurposing against cancer. Auranofin mainly targets the anti-oxidative system catalyzed by thioredoxin reductase (TrxR), which protects the cell from oxidative stress and death in the cytoplasm and the mitochondria. TrxR is over-expressed in many cancers as an adaptive mechanism for cancer cell proliferation, rendering it an attractive target for cancer therapy, and auranofin as a potential therapeutic agent for cancer. Inhibiting TrxR dysregulates the intracellular redox state causing increased intracellular reactive oxygen species levels, and stimulates cellular demise. An alternate mechanism of action of auranofin is to mimic proteasomal inhibition by blocking the ubiquitin–proteasome system (UPS), which is critically important in cancer cells to prevent cell death when compared to non-cancer cells, because of its role on cell cycle regulation, protein degradation, gene expression, and DNA repair. This article provides new perspectives on the potential mechanisms used by auranofin alone, in combination with diverse other compounds, or in combination with platinating agents and/or immune checkpoint inhibitors to combat cancer cells, while assessing the feasibility for its repurposing in the clinical setting.
Editor: New York: Springer US
Idioma: Inglés

Enlaces

View this record in MEDLINE/PubMed

Volver a la lista de resultados

Anterior Resultado 4 Siguiente Ir a la siguiente página

Realización: Logos de Redes Sociales:

The gold complex auranofin: new perspectives for cancer therapy

Abdalbari, Farah H. ; Telleria, Carlos M.

New York: Springer US

Buscando en bases de datos remotas, por favor espere